Repurposed Drugs in Gastric Cancer.
Diana AraújoEduarda RibeiroIrina AmorimNuno ValePublished in: Molecules (Basel, Switzerland) (2022)
Gastric cancer (GC) is one of the major causes of death worldwide, ranking as the fifth most incident cancer in 2020 and the fourth leading cause of cancer mortality. The majority of GC patients are in an advanced stage at the time of diagnosis, presenting a poor prognosis and outcome. Current GC treatment approaches involve endoscopic detection, gastrectomy and chemotherapy or chemoradiotherapy in an adjuvant or neoadjuvant setting. Drug development approaches demand extreme effort to identify molecular mechanisms of action of new drug candidates. Drug repurposing is based on the research of new therapeutic indications of drugs approved for other pathologies. In this review, we explore GC and the different drugs repurposed for this disease.
Keyphrases
- poor prognosis
- papillary thyroid
- locally advanced
- rectal cancer
- long non coding rna
- gas chromatography
- end stage renal disease
- squamous cell
- ejection fraction
- drug induced
- newly diagnosed
- cardiovascular disease
- early stage
- lymph node
- lymph node metastasis
- squamous cell carcinoma
- peritoneal dialysis
- climate change
- type diabetes
- radiation therapy
- coronary artery disease
- young adults
- combination therapy
- loop mediated isothermal amplification